Advancing excellence in laboratory medicine for better healthcare worldwide

IFCC - Scientific Division (SD)

SD Executive Committee in Durban (ZA) for the SD Meeting and IFCC WorldLab Congress

 

From left to right:
Gary Myers
- JCTLM Consultant; Karen Phinney, NIST Consultant; James Pierson-Perry - Corporate Representative; Konstantinos Makris - Member; Paola Bramati - IFCC office;  Joseph Passarelli - Secretary; Philippe Gillery - Chair

 

The Scientific Division (SD)

A Committee on Standards was established in 1966 "to instigate and promote theoretical and practical developments in the field of standards and standardisation in clinical chemistry - in its broadest sense." During its first decade, the main efforts of the Committee were directed toward (1) analytical nomenclature, (2) reference materials and methods, and (3) quality control. Its achievements during this period are illustrated by the list of publications on these topics. Following a Council decision in 1978, efforts have been made to extend its work to include more subjects of interest both to clinicians and clinical chemists and laboratorians. Accordingly, the name of the Committee was changed to the Scientific Committee and later to the Scientific Division.

The Division and its activities are managed by an Executive Committee. This Committee is responsible for (1) developing a mission statement, (2) developing strategy and tactics, (3) initiating and managing projects, and (4) generating and adhering to its Terms of Reference.

Mission Statement

The mission of the SD is to advance the science of Clinical Chemistry and Laboratory Medicine and to apply it to the practice of Clinical Laboratory Science. 

SD Strategy

According to the Statutes of IFCC, the Federation exists to advance the science and practice of Clinical Chemistry and to further its application in the provision of health services and the practice of medicine. The goals to which the Scientific Division is committed are to:

  • Identify research areas of relevance to Clinical Chemistry and Laboratory Medicine and assist the transfer of research results to the profession.
  • Identify scientific and technological problems in current practice and provide solutions and guidelines on how to resolve them.
  • Facilitate the development and transfer of technical innovations to clinical laboratory professionals and clinicians.
  • Facilitate the development and implementation of diagnostic strategies.
  • Establish standards for scientific and technical aspects of good laboratory practice.
  • Facilitate the development of reference measurement processes and the production of reference materials
  • Establish networks of reference laboratories
  • Respond to scientific and technical needs of IFCC Member Societies, IFCC Corporate Members and external agencies.
  • Participate actively in the scientific programmes of IFCC congresses and other scientific meetings.
  • Ensure the quality of IFCC scientific documents.
  • Organise Master Discussions

SD Projects

The SD initiates and manages projects with its own resources or through its Committees and Working Groups. Work is conducted in cooperation with other IFCC units and with relevant National and International Organisations. The SD ensures that each of its Committees and Working Groups are functioning under clear terms of reference together with an agreed schedule of activity. The SD will assist in the development of the project proposals, and will undertake an annual review of progress and review and approve any documents that result from the work.

 

SD Executive Committee (SD-EC)

Name Position Country Term Time in Office
P. Gillery Chair FR 1st 2017 01 - 2019 12
C.M.  Cobbaert Vice-Chair NL 1st 2017 01 - 2019 12
J. Passarelli Secretary US 2nd 2018 01 - 2020 12
B. Das Member IN 1st 2018 06 - 2020 12
K. Makris Member GR 1st 2017 01 - 2019 12
M. Plebani Member IT 1st 2017 02 - 2019 12
J.F. Pierson-Perry Corporate Member US 2nd 2018 02 - 2020 12
G. Myers JCTLM Chair / SD Consultant US    
H. Schimmel JRC Observer BE
Y. Wang NIFDC Observer CN
C. Burns NISBC Consultant UK
K. Phinney NIST Consultant US

 

Chairs of Scientific Division's Committees and Working Groups

 

Committees

8.2.06 Nomenclature, Properties and Units (C-NPU) in collaboration with International Union of Pure and Applied Chemistry (IUPAC) K. Toska (NO)
8.2.11 Molecular Diagnostics (C-MD) D. Payne (US)
8.2.23 Traceability in Laboratory Medicine (C-TLM) A. Kessler (DE)
8.2.24 Reference Intervals and Decision Limits (C-RIDL) Y. Ozarda (TR)
8.2.25 Standardization of Thyroid Function Tests (C-STFT) H. Vesper (US)
8.2.26 Harmonization of Autoimmune Tests (C-HAT) J. Sheldon (UK)

Working Groups

8.3.35 Standardisation of Hemoglobin A2 (WG-HbA2) A. Mosca (IT)
8.3.36 Carbohydrate-Deficient Transferrin (WG-CDT) J. Deenmamode (UK)
8.3.39 Standardisation of Albumin Assay in Urine (WG-SAU) in collaboration with National Kidney Disease Education Program (NKDEP) L. Bachmann (US)
8.3.40 Standardisation of Pregnancy-Associated Plasma Protein A (WG-PAPP A) S. Wittfooth (UK)
8.3.41 Growth-Hormone (WG-GH) E. Lentjes (NL)
8.3.42 Standardisation of Insulin Assays (WG-SIA) in collaboration with American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) A. Saenger (US)
8.3.43. Standardisation of Troponin I (WG-TNI) C. Robertson (US) 
8.3.48 Parathyroid Hormone (WG-PTH) C. Sturgeon (UK)
8.3.49 CSF Proteins (WG-CSF) K. Blennow (SE)
8.3.50 Standardisation of Bone Markers Assays in collaboration with IOF (WG-SBMA)  H. Morris (AU)
8.3.51 Commutability (WG-C) G. Miller (US)
8.3.53 Immunosuppressive Drugs (WG-ID) C. Seger (CH)
8.3.54 Apolipoproteins by Mass Spectrometry (WG-APO MS) C. Cobbaert (NL)
8.3.55 Pancreatic Enzymes (WG-PE) D. Grote-Koska (DE)
8.3.56 Fecal Immunochemical Testing (WG-FIT) S. Benton (UK)
8.3.57 Cell free DNA and related circulating biomarkers (WG-cfDNA) R. van Schaik (NL)
8.3.58 Procalcitonin (WG-PCT) V. Delatour (FR)
8.3.59 Vitamin D Standardization Program (WG-Vit D) C. Sempos (US)

 

SD Executive Committe's contacts 

 

CHAIR

Prof. Philippe GILLERY
Laboratory of Biochemistry-Pharmacology-Toxicology 
Medical Biology and Pathology Division
Maison Blanche Hospital
University Hospital of Reims
45 rue Cognacq Jay
51092 Reims Cedex - France
Tel: +33 3 2678 3952
Fax: +33 3 2678 3882
E-mail: pgillery@chu-reims.fr

VICE-CHAIR

Prof. Christa M. COBBAERT
Clinical Chemist Head of the Department
of Clinical Chemistry
Leiden University Medical Center
Postbus 9600 Postzone E2-P
2300 RC Leiden - The Netherlands
Tel: +31 71 5262278/+31 71 5264483
Fax : +31 71 52666753
E-mail: C.M.Cobbaert@lumc

SECRETARY

Mr. Joseph PASSARELLI
Scientific Relations, Research and Development
Roche Diagnostics Corporation
9115 Hague Road, PO Box 50416
Indianapolis, Indiana 46250-0416 - USA
Tel: +1 317 521 4206
Fax: +1 317 521 2324
Mobile: +1-317-625-7810
E-mail: joseph.passarelli@roche.com

MEMBER

Dr. Barnali DAS
Consultant, Biochemistry & Immunology Division,
Kokilaben Dhirubhai Ambani Hospital &
Medical Research Institute,
Four Bunglows, Andheri (West)
Mumbai 400053 - India
Tel: +91-22-30970734
Mobile: +91-9324349519
E-mail: barnali.das@relianceada.com; drbarnalid@gmail.com

MEMBER

Dr. Konstantinos MAKRIS
Clinical Biochemist
Clinical Biochemistry Department
KAT General Hospital
2 Nikis street, 14561
Kifissia, Athens - Greece
Phone: +30-213-2086701
Mobile: +30-6972207867
e-mail: kostas.makris.km@gmail.com

MEMBER

Prof. Mario PLEBANI
Full Professor of Clinical Biochemistry and
Clinical Molecular Biology
Chief Department of Laboratory Medicine
University Hospital - Padova
Dean of the Medical School
University of Padova - Italy
E-mail: mario.plebani@unipd.it

CORPORATE REPRESENTATIVE

Mr. James F. PIERSON-PERRY
Principal Key Expert
Global Assay Development, Glasgow Site
Siemens Healthcare Diagnostics
USA
Tel: +302.631.7692
Mobile: +302.229.6462
Fax: +302.631.7487
e-mail: james.f.pierson-perry@siemens-healthineers.com

EUROPEAN COMMISSION - JRC OBSERVER

Dr. Heinz SCHIMMEL
Project Officer
Directorate General Joint Research Centre
Directorate F – Health
Consumers and Reference Materials
Reference Materials Unit
Retieseweg 111
2440 Geel - Belgium
Tel: +32 (0)14 571 720
E-mail: heinz.schimmel@ec.europa.eu

ICHCLR OBSERVER

Dr. Greg MILLER
Professor of Pathology
Co-Director of Clinical Chemistry
Director of Pathology Information Systems
Virginia Commonwealth University Health System
Richmond, VA 23298-0286 - USA
Tel:  +1.804.828.0375
Email: greg.miller@vcuhealth.org

JCTLM CONSULTANT

Dr. Gary L. MYERS
Chair, JCTLM
4711 Derby Lane
Smyrna, GA 30082 - USA
Tel: +404-457-5804
E-mail: gmyers1049@yahoo.com 

NIBSC CONSULTANT

Dr. Chris BURNS
Head, Biotherapeutics Division
National Institute for Biological Standards and Control (NIBSC)
A Centre of the MHRA, Blanche Lane
South Mimms, Potters Bar
Hertfordshire, EN6 3QG - UK
Tel: 01707 641247
Email: Chris.Burns@nibsc.org

NIFDC OBSERVER

Prof. Youchun WANG 
Deputy Director General
National Institutes for Food and Drug Controls (NIFDC)
P.R. China
E-mail: wangyc@nifdc.org.cn

NIST CONSULTANT

Dr. Karen W. PHINNEY
Leader, Bioanalytical Science Group
Biomolecular Measurement Division
National Institute of Standards and Technology (NIST)
100 Bureau Drive, Stop 8314
Gaithersburg, MD 20899-8314 - USA
Tel.: +1 (301) 975-4457
E-mail: karen.phinney@nist.gov

 

 

 

 
Website developed by Insoft Digital